Adage Capital Partners Gp, L.L.C. Annovis Bio, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $52.3 Billion
- Q2 2024
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Annovis Bio, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 100,000 shares of ANVS stock, worth $824,000. This represents 0.0% of its overall portfolio holdings.
Number of Shares
100,000
Previous 250,000
60.0%
Holding current value
$824,000
Previous $2.98 Million
80.64%
% of portfolio
0.0%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding ANVS
# of Institutions
52Shares Held
975KCall Options Held
647KPut Options Held
1.58M-
Vanguard Group Inc Valley Forge, PA361KShares$2.98 Million0.0% of portfolio
-
Black Rock Inc. New York, NY101KShares$829,8420.0% of portfolio
-
Geode Capital Management, LLC Boston, MA76.2KShares$628,1590.0% of portfolio
-
Wescott Financial Advisory Group, LLC41.6KShares$342,8410.03% of portfolio
-
Sterling Investment Advisors, Ltd.33.5KShares$275,8250.06% of portfolio
About Annovis Bio, Inc.
- Ticker ANVS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 8,163,920
- Market Cap $67.3M
- Description
- Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...